RRMS patients started on high-efficacy treatments may have less reduction in work capacity than those on moderate-efficacy ...

The PoNS device has shown significant benefits in walking and balance in clinical trials, and benefits were seen in ...

The number of mitochondrial DNA copies may drop as MS progresses, suggesting a possible biomarker for disease progression, a ...

Quantum Biopharma plans to file an application by year's end seeking FDA clearance for a Phase 2 clinical trial testing Lucid ...